Stereotactic injection of murine brain tumor cells for neuro-oncology studies

Glioblastomas (GBMs) are the most common and aggressive brain tumors, with a poor prognosis. Effective preclinical models are crucial to investigate GBM biology and develop novel treatments. Syngeneic models, which consist in injecting murine GBM cells into mice with a similar genetic background, of...

Full description

Saved in:
Bibliographic Details
Published inMethods in cell biology Vol. 192; pp. 181 - 188
Main Authors Daviaud, Camille, Lira, María Cecilia, Vanpouille-Box, Claire, De Martino, Mara
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 2025
Subjects
Animals
Brain Neoplasms - pathology
Cell Line, Tumor
Disease Models, Animal
Glioblastoma
Glioblastoma - pathology
Humans
Immunotherapy
Mice
Murine brain tumors
Neoplasm Transplantation - methods
Stereotactic injection
Stereotaxic Techniques
Surgery
Stereotactic injection
Murine brain tumors
Surgery
Immunotherapy
Glioblastoma
Online AccessGet full text

Cover

More Information
Summary:Glioblastomas (GBMs) are the most common and aggressive brain tumors, with a poor prognosis. Effective preclinical models are crucial to investigate GBM biology and develop novel treatments. Syngeneic models, which consist in injecting murine GBM cells into mice with a similar genetic background, offer reproducibility, cost-effectiveness, and an intact immune system, making them ideal for immunotherapy research. This chapter presents a comprehensive protocol for stereotactic injection of murine GBM cells into immunocompetent mice to induce intracranial GBM. The protocol covers cell culture, anesthesia, surgical procedures, and post-operative care, allowing the reliable induction of orthotopic brain tumors. This method can be used to study anti-GBM therapies, including immunotherapies, and has the potential to accelerate the development of effective treatments.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0091-679X
DOI:10.1016/bs.mcb.2024.07.005